American Financial Group, Inc. 5.125% Subordinated Debentures due 2059 Stock (NYSE: AFGC)

American Financial Group, Inc. 5.125% Subordinated Debentures due 2059 (NYSE:AFGC) Stock, Quote.Headers.trade-ideas

Cannabis

News

Small Cap

Markets

AFCG

AFGC

AFC Gamma, Inc. (NASDAQ: AFCG) revealed Thursday the nomination and appointment of Marnie Sudnow to its board of directors. 

AFC Gamma Appoints Marnie Sudnow To Its Board of Directors

Penny Stocks

AUSAF

GRYN

KERN

SILFF

SORWF

Benzinga’s Cannabis Insider is a live daily show for cannabis investors.

Guests:

Video: Benzinga Cannabis Insider 6/24 Ft. Akerna &amp; Viridian Sciences

Intraday Update

Movers

Trading Ideas

AACG

AAOI

ABCB

ABMD

ACCO

ACEL

ACGL

ACHC

ACHV

ACIU

ACRE

ACRX

ACST

ACTG

ADES

ADMP

ADMS

ADNT

ADOM

ADPT

ADTN

AEHR

AEIS

AERI

AEZS

AFIN

AFMD

AGFS

AGLE

AGRO

AGYS

AIMC

AIMT

AINV

AIRT

AKCA

AKTS

AKTX

ALBO

ALDX

ALEX

ALGN

ALGT

Stocks That Hit 52-Week Lows On Monday

American Financial Group, Inc. 5.125% Subordinated Debentures due 2059

Biotech

General

Standard BioTools Sets New Record With Expanded SomaScan 11K Platform, Offering 11,000 Protein Measurements Across Multiple Sample Types Including Cerebrospinal Fluid And Tissue Homogenates

Management

CRMT

America's Car-Mart Appoints Jamie Fischer As COO

Waste Management, Inc., a Delaware corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) ("WM"), announced today that it has received, on behalf of Stericycle, Inc., a Delaware corporation ("SRCL"), the requisite consents to amend the 3.875% Senior Notes due 2029 (the "SRCL Notes") issued by SRCL and the indenture governing the SRCL Notes (the "SRCL Indenture") to eliminate substantially all of the restrictive covenants and events of default, other than payment-related, guarantee-related and bankruptcy-related events of default (collectively, the "Proposed Amendments"), based on the early tender results in connection with WM's previously announced (i) private offer to exchange (the "Exchange Offer") any and all of the $500 million aggregate principal amount outstanding of SRCL Notes held by eligible holders for a series of new notes to be issued by WM (the "WM Notes"), and (ii) WM's related solicitation of consents, on behalf of SRCL (the "Consent Solicitation"), to adopt the Proposed Amendments, pursuant to the terms and subject to the conditions set forth in an exchange offer memorandum and consent solicitation statement, dated September 10, 2024 (the "Offering Memorandum").

Offerings

WM Announces Successful Early Tender Results In Private Exchange Offer And Consent Solicitation For Any And All Of Stericycle $500M Outstanding 3.875% Senior Notes Due 2029

Thor Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading lower on Tuesday.</a>
The company reported fourth-quarter earnings per share of $1.68, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40998065/thor-industries-announces-fourth-quarter-fiscal-2024-results" rel="noreferrer noopener">beating the street view of $1.43</a>. Quarterly sales of $2.534 billion (down 7.4%) outpaced the analyst consensus of $2.471 billion.
North American Towable RV net sales were up 0.1% for the fourth quarter, North American Motorized RV net sales decreased 21.2%, and European RV net sales decreased 7.4% on a year over year basis. Quarterly gross profit margin expanded by 140 basis points to 15.8%.
&#8220;We realized strong margin performance relative to the current market conditions as our teams executed on strategic initiatives designed to maximize our operational efficiency. This long-term focus puts THOR in a strong position for our Fall Open House event and the coming winter season,&#8221; said Bob Martin, President and CEO of the company.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/40998340/nasdaq-s-p-500-futures-firm-chinas-economic-stimulus-fuels-commodities-bitcoin-steady-heres-what-tr" rel="noreferrer noopener">Nasdaq, S&amp;P 500 Futures Firm, China&#8217;s Economic Stimulus Fuels Commodities, Bitcoin Steady: Here&#8217;s What Traders Should Be Watching Tuesday</a>
Thor Industries exited the quarter with cash and equivalents worth $501.32 million. Inventories as of quarter end totaled $1.366 billion. 
Outlook: Thor Industries anticipates fiscal year 2025 sales between $9.0 billion and $9.8 billion, compared to the $10.49 billion estimate, and expects EPS to range from $4.00 to $5.00, below the estimated $6.65.
&#8220;Our base assumption for forecasting will be that the macro challenges will persist through our fiscal year 2025, which runs from August 1, 2024 through July 31, 2025. In North America, we expect discounting in fiscal 2025 to remain elevated in our Motorized segment, while we expect discounts to slightly moderate in our Towable segment,&#8221; the company said.
Price Action: THO shares are trading lower by 2.97% to $100.12 premarket at last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40969515/amazon-going-nuclear-hiring-plans-indicate-company-may-be-eyeing-nuclear-to-meet-energy-needs" target="_blank" rel="noreferrer noopener">Amazon Going Nuclear? Hiring Plans Indicate Company May Be Eyeing Nuclear To Meet Energy Needs</a></li>
</ul>

Earnings

Equities

Guidance

Thor Industries Faces Bumpy Road Ahead: Q4 Earnings Beat, But FY25 Forecast Falls Short

Tuesday, UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>)&nbsp;and&nbsp;Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)&nbsp;released topline results from the Phase 3 PHOENYCS GO study of dapirolizumab pegol for moderate-to-severe systemic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40994898/ucb-and-biogen-announce-positive-topline-results-from-phase-3-study-of-dapirolizumab-pegol-in-syst" rel="noreferrer noopener">lupus erythematosus (SLE)</a>.
SLE is&nbsp;a chronic autoimmune disease that can affect many organs in the body.&nbsp;It occurs when the body&#8217;s immune system attacks healthy tissue, causing inflammation and sometimes permanent tissue damage.
SLE can present itself in several ways, including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures or psychosis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514109/biogens-alzheimers-drug-secures-uk-approval-but-an-independent-agency-does-not-recommend-reimburs" rel="noreferrer noopener">Biogen&#8217;s Alzheimer&#8217;s Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement</a>.
Dapirolizumab pegol, in addition to standard-of-care (SOC) treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity after 48 weeks versus placebo in addition to SOC. The study enrolled 321 patients.
Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.
The safety profile of dapirolizumab pegol was generally consistent with previous studies and with that expected in study participants with systemic lupus erythematosus receiving an immunomodulator.
UCB and Biogen are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY.
Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.
Detailed results from the PHOENYCS GO study will be presented at an upcoming medical congress.
Price Action: At last check Tuesday, BIIB stock was up 1.66% at $199.06 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40997350/totalenergies-secures-7-year-lng-deal-with-hd-hyundai-chemical-expanding-reach-in-asias-energy-m" target="_blank" rel="noreferrer noopener">TotalEnergies Secures 7-Year LNG Deal With HD Hyundai Chemical: Expanding Reach In Asia&#8217;s Energy Market</a>.</li>
</ul>

Large Cap

Health Care

BIIB

UCBJF

UCBJY

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

NV5 Global, Inc. (the "Company" or "NV5") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>), a provider of technology, certification, and consulting solutions, announced today that it has been awarded a prime contract with the National Geospatial-Intelligence Agency (NGA) to provide unclassified commercial geospatial intelligence (GEOINT)-derived computer vision and analytic services under the Luno A program. &nbsp;
"We are pleased to have been selected by NGA to support the national intelligence community through GEOINT-derived analytics," said Dickerson Wright, PE, Executive Chairman of NV5. "NV5 has built a reputation supporting NGA's mission for over 20 years, and we look forward to expanding our relationship with NGA and the value we deliver to the agency through the Luno A program."
The $290 million contract is a five-year, multiple-award indefinite delivery, indefinite quantity contract to monitor global economic and environmental activity, as well as military capabilities. The contract will leverage commercial computer vision and artificial intelligence capabilities and will integrate into analytic workflows for the national security community's operational use. NV5 anticipates that it will receive approximately $30 million in revenue over the term of the Luno A contract.

Contracts

NVEE

National Geospatial-Intelligence Agency Selects NV5 For Geospatial Contract Valued Up To $290M

MDAI

Spectral AI Reaches 25% Patient Enrollment At Emergency Departments For Its US Burn Pivotal Study And Adds Two Clinical Trial Sites

VSAT

Viasat Awarded $33.6M U.S. Air Force DEUCSI Contract To Develop Phased Array Antenna Technology For Resilient Satellite Communications In Tactical Aircraft

<ul>
<li>Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense&#xAE; in Early-Stage Low Risk Breast Cancer scheduled for November 7, 2024</li>
<li>96.3% recurrence free rate for women treated with ProSense&#xAE; cryoablation and endocrine therapy; 100% of patients and treating physicians were satisfied with the cosmetic outcome.</li>
<li>Lead study author, Dr. Richard E. Fine, is an ICE3 investigator and winner of the 2024 American Society of Breast Surgeons' Scientific Impact Award for his presentation of the ICE3 trial data.</li>
<li>ProSense&#xAE; offers women the choice of a quick minimally invasive in-office procedure under local anesthesia with minimal pain, minimal scarring and rapid recovery as compared to lumpectomy which involves full anesthesia and hours of surgery and recovery, followed by 1-2 weeks of limited movement.</li>
</ul>
CAESAREA, Israel, Sept. 24, 2024 /PRNewswire/ -- <a href="https://icecure-medical.com/">IceCure Medical Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an article titled, "Cryoablation Without Excision for Early–Stage Breast Cancer: ICE3 Trial 5–Year Follow–Up on Ipsilateral Breast Tumor Recurrence" in the Annals of Surgical Oncology, the official journal of the Society of Surgical Oncology. The open access article, which is available <a href="https://link.springer.com/article/10.1245/s10434-024-16181-0">HERE</a>, presents the results of IceCure's ICE3 trial, the largest controlled multicenter clinical trial ever completed in the U.S. for liquid nitrogen ("LN2") based cryoablation of small, low-risk, early-stage malignant breast tumors as an alternative to surgery. The lead author of the study is Dr. Richard Fine, an ICE3 Investigator, who co-authored the publication with 24 doctors who are&nbsp;ProSense&#xAE; users including co-primary investigator, Dr. Kenneth Tomkovich.

ICCM

IceCure's ICE3 5-Year Trial Results Published In The Peer Reviewed Annals Of Surgical Oncology Journal: ProSense Cryoablation Without Excision For Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

NVRO

Nevro Launches AI-Driven HFX AdaptivAI, The First AI-Powered Spinal Cord Stimulation Technology, Following FDA Approval For Personalized Pain Relief

Susquehanna analyst Joseph Stauff maintains Light &amp; Wonder (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) with a Neutral and lowers the price target from $92 to $90.

Price Target

Analyst Ratings

Susquehanna Maintains Neutral on Light & Wonder, Lowers Price Target to $90

Drug developers &amp; researchers can now leverage the CleanScribe enzyme to reduce dsRNA formation by up to 85% in mRNA synthesis without compromising mRNA yield, capping efficiency, or integrity
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2F&amp;esheet=54126229&amp;newsitemid=20240924933319&amp;lan=en-US&amp;anchor=TriLink+BioTechnologies&amp;index=1&amp;md5=563328b74545a165ddc9c6b622ee3dd5">TriLink BioTechnologies</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alpha-zyme.com%2F&amp;esheet=54126229&amp;newsitemid=20240924933319&amp;lan=en-US&amp;anchor=Alphazyme&amp;index=2&amp;md5=57c66a008ab28e3b273c9fcef3ee76cf">Alphazyme</a>, both part of Maravai LifeSciences, have collaborated to launch <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fcleanscribe-rna-polymerase.html&amp;esheet=54126229&amp;newsitemid=20240924933319&amp;lan=en-US&amp;anchor=CleanScribe%26%238482%3B+RNA+Polymerase&amp;index=3&amp;md5=6353d22764713b43994b67950b7cd888">CleanScribe&#x2122; RNA Polymerase</a>, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production. The new product reduces dsRNA by up to 85%, helping to develop safer, more potent mRNA therapeutics.
CleanScribe RNA Polymerase is a novel DNA-dependent RNA polymerase that catalyzes the in vitro transcription (IVT) of a recombinant gene regulated by the T7 promoter. During the IVT reaction, dsRNA can be produced as a byproduct, which can trigger undesirable inflammatory responses in host cells. The CleanScribe enzyme drastically reduces dsRNA formation during IVT by up to 85% compared to wild-type T7 RNA Polymerase.

MRVI

TriLink BioTechnologies And Alphazyme, Both Part Of Maravai Lifesciences, Have Collaborated To Launch CleanScribe RNA Polymerase, A Novel Enzyme That Reduces Double-Stranded RNA In mRNA Production

LIPO

Lipella Pharmaceuticals Announces Update On Phase 2a Trial Of LP-310 In Oral Lichen Planus; Three Participants Completed The Four-week Treatment, Says Treatment Was Well Tolerated And Had No Unpleasant Taste

As It Celebrates 40th Year And Expands AI Leadership; $9B Returned To Shareholders Since 2023

DELL

Dell Technologies Rejoins S&P 500 Index

The landscape of America&#8217;s <a href="https://www.benzinga.com/top-stories/24/09/40945913/as-the-ai-arms-race-wages-on-amazon-takes-shot-at-rival-adobe-with-new-text-to-video-product">tech industry has undergone a transformation</a> in recent years. While <a href="https://www.benzinga.com/news/24/01/36675795/silicon-valley-billionaires-want-to-build-their-own-eco-friendly-city-in-california-but-critics-smel">Silicon Valley is still the powerhouse</a>, a new crop of cities is emerging as tech hubs, helping reshape local economies and real estate markets.
According to a report issued by Mansion Global, several up-and-coming tech centers are attracting major companies and top talent, driving up home values in their respective areas.&nbsp;
Don't Miss:
<ul>
<li>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Here's how you can invest in the city before that happens</a>.</li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>
<h2 class="wp-block-heading">Atlanta</h2>
Atlanta is becoming a hotbed for financial technology (fintech). According to the report, the city now processes 70% of all global financial transactions. That infrastructure has paved the way for a fintech scene where companies like Fiserv, BitPay, and Kabbage compete with traditional banking giants.
The tech boom isn&#8217;t limited to fintech, though. Major players like Panasonic, Intel and Google have established their presence in the city, with Google opening a new 500,000-square-foot office in July 2022.
According to the report, the influx of tech jobs—currently numbering around 112,000 across 8,500 companies—is reshaping Atlanta&#8217;s real estate market. The combination of high-paying jobs, top-notch universities, and a relatively low cost of living makes the city increasingly attractive to companies and tech workers, putting upward pressure on home values.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Salt Lake City</h2>
Salt Lake City&#8217;s tech roots date back to 1976 when WordPerfect was created at Brigham Young University. Today, the city has blossomed into a full-fledged tech hub, boasting a workforce of over 59,600 tech professionals, according to the Mansion Global report.
The city&#8217;s tech scene is diverse, spanning established names like Adobe and eBay to homegrown successes like Overstock.com and Instructure. The startup ecosystem is particularly vibrant, with nearly 70% of all venture capital funding in Salt Lake City – totaling almost $130 million – directed toward tech ventures.
The tech boom has impacted Salt Lake City&#8217;s job market and real estate. As tech talent flocks to the area, home values are increasing.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Investing in its booming real estate market has never been more accessible.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Las Vegas</h2>
Las Vegas is diversifying beyond its traditional entertainment and hospitality focus, with tech emerging as a key driver of economic growth. The city is carving out sports tech and fintech niches, attracting companies like DraftKings, Sleeper and Shift4.
The expansion of major league sports in Las Vegas – including the NHL&#8217;s Golden Knights, the NFL&#8217;s Raiders and the upcoming relocation of MLB&#8217;s Athletics – has created a ground for sports tech. DraftKings, for instance, opened a 90,000-square-foot technology hub in the city in March 2023.
Mansion Global noted that the sports tech workforce in Las Vegas is expected to grow from 7,700 in 2023 to 9,600 by 2028. The fintech sector is similarly strong, with over 15,700 employees as of 2022 and projections for continued growth.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Northern Virginia</h2>
Northern Virginia&#8217;s tech scene gained national attention in 2018 when Amazon announced plans for its second headquarters in Arlington and Alexandria. However, the region&#8217;s tech roots run much deeper, dating back to AOL&#8217;s founding in Loudoun County in the late 1980s.
Today, Northern Virginia is home to diverse tech companies, from giants like Amazon, Google and Microsoft to defense contractors with tech operations, like General Dynamics and Northrop Grumman.
The impact on the local real estate market has been substantial. With Amazon projecting to employ 25,000 people at its National Landing headquarters by 2031, housing demand in the area is skyrocketing, the report said.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Elon Musk&#8217;s secret mansion in Austin revealed through court filings.<a href="https://www.benzinga.com/money/elon-musk-secret-mansion-austin-nada"> Here&#8217;s how to invest in the city&#8217;s growth before prices go back up.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Raleigh</h2>
Raleigh, part of North Carolina&#8217;s Research Triangle, has long been a center of innovation. However, recent years have seen the city&#8217;s tech scene expand beyond its traditional strengths in big data and biotech to encompass emerging fields like clean tech, cybersecurity and artificial intelligence.
The city&#8217;s tech ecosystem includes established giants like IBM, Cisco and Epic Games and a startup scene. The Triangle Tweener List, which tracks local startups, now includes some 300 companies across various tech sectors.
Staffing agency Hatch I.T. has predicted that Raleigh will become the second-largest tech hub on the East Coast by 2025, surpassed by Washington, D.C. That growth transforms downtown Raleigh, sparking a real estate boom that&#8217;s turning the once predominantly governmental and commercial area into a residential and cultural center.
As the five cities continue cementing their status as tech hubs, their real estate markets will likely grow. Read Next:
<ul>
<li>Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://benzinga.com/money/rory-mcilroys-florida-mansion-doubled-in-value"> here&#8217;s how to get started investing in real estate with just $100</a></li>
<li>Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a></li>
</ul>

Real Estate

Five Emerging Tech Cities Where Home Values Are Surging Alongside Innovation

Susquehanna analyst Charles Minervino initiates coverage on Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral rating and announces Price Target of $62.

Initiation

Susquehanna Initiates Coverage On Valaris with Neutral Rating, Announces Price Target of $62

WIIM

TRNR

Interactive Strength shares are trading higher after the company announced that CLMBR passed EU-wide compliance requirements

CLEAR Expands TSA PreCheck Enrollment And Renewal Services With Four New Locations, Including San Antonio And Buffalo Niagara Airports; Now Operating At 51 U.S. Locations

<ul>
<li>U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025</li>
<li>Almost half of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp</li>
<li>Supplemental New Drug Application (sNDA) supported by positive efficacy and safety data from Phase 2b and pivotal Phase 3 trials, and long-term ZORYVE cream plaque psoriasis program &nbsp;</li>
</ul>
WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KIeqveaDQX7yDbtQmBYbYGS60zB7UAImm5fncsFaGQRGkqjxKDJJj88exm7xues1TD0CzdcQ9Z9oFnKZaVdwYA_o-UuMhRo1cdu5-Sbcf7k=">Arcutis Biotherapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis. The FDA assigned the application a PDUFA target action date of May 22, 2025.

ARQT

FDA Accepts Arcutis' Supplemental New Drug Application For ZORYVE Foam For The Treatment Of Scalp And Body Psoriasis In Adults And Adolescents Ages 12 and Over

Benchmark analyst Josh Sullivan reiterates AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) with a Buy and maintains $83 price target.

Reiteration

Benchmark Reiterates Buy on AAR, Maintains $83 Price Target

American Financial Group: A Yield Of Over 5.00% On Debentures

My Top Insurance Picks In Early 2024

American Financial Group, Inc. 2023 Q4 - Results - Earnings Call Presentation

American Financial Group, Inc. (AFG) Q4 2023 Earnings Call Transcript

Beyond Cash: Maximizing Income With Investment Grade Baby Bonds

American Financial Group, Inc. (AFG) Q1 2024 Earnings Call Transcript

American Financial: Debentures Better Than Dividends For Income Investors

American Financial Group, Inc. (AFG) Q2 2024 Earnings Call Transcript

I Am Buying Investment-Grade Bonds And Preferreds For An Upcoming Recession

Fidelity Select Financials Portfolio Q2 2024 Review

ACGLN

ACGLO

AFGB

AFGD

AFGE

APOS

BACRP

BWIN

CGABL

CTVA

EWBC

FCFS

HTLF

HTLFP

KKRS

LGGNF

LGGNY

OXLC

OXLCL

OXLCM

OXLCN

OXLCO

OXLCP

OXLCZ

PYPL

SCHD

SPGI

TRRSF

WFCNP

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

American Financial Group, Inc. 5.125% Subordinated Debentures due 2059

American Financial Group, Inc. 5.125% Subordinated Debentures due 2059 (AFGC) Forecast

American Financial Group, Inc. 5.125% Subordinated Debentures due 2059 (NYSE:AFGC) Stock, Quote.Headers.trade-ideas